Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: BioBait who wrote (3352)	8/15/2021 9:23:03 PM
From: CuttingEdge Bio	Respond to of 3557

The only problem with this approach is people want a fast-acting pill that can be immediately prescribed and easily dosed, for mass deployment, as soon as people test positive, not another antibody approach. (Although I don't doubt the combo with antigen specific antibodies, for example together with regen-cov probably will have even more powerful efficacy). In my view, REGN has a lot of work to do to characterize how to dose (and work to do to characterize the benefit, whatever it may be) with regen-cov in already-vaccinated breakthrough cases. Whatever happened to camostat mesylate, which was talked about very early in the pandemic as an existing tmprss2 inhibitor?